Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC

More documents

Recommendations

Info

36 TABLE 10. Epidemiology and Surveillance Facilities (cont’d) BRITISH COLUMBIA Facility (URL) Description Contact Centre for Clinical Epidemiology & Evaluation (C2E2), VCHRI (www.c2e2.vchri.ca/) Described above in Table 9. Centre for Health Evaluation and Works in areas of epidemiology and Orr, John. Director of Operations. Outcome Sciences (CHEOS) (www. population health. See also Tables 3 and Tel: 604-806-2294. cheos.ubc.ca) 9. johnorr@mail.cheos.ubc.ca CFRI Clinical Research Support Unit Offers expertise in epidemiology, statistics Junker, Anne, Director, Clinical & Popula(www.cfri.ca/research_support/clini- and economics. See Appendix 2. tion Health Studies, CFRI. cal_research_support/default.asp) T: 604-875-3591. ajunker@cw.bc.ca Immunity & Infection Research Collaborative team of basic scientists, Helm, Jeffrey. Research Co-ordinator. Centre (IIRC), VCHRI (www.iirc.ca/Immu- clinicians, and health professionals whose T: 604-875-4111 x 68576. nity_and_Infection_Research_Centre. expertise includes epidemiology, health jhelm@interchange.ubc.ca htm) care delivery, and policy development. Integrated Public Health Informa- Automated, integrated, client health re- Sandrin, Dilma. iPHIS Program Manager, tion System (iPHIS) cord and reporting system that supports BCCDC. (www.phac-aspc.gc.ca/php-psp/ciphs- public health provider interventions, T: 604-707-2501. eng.php#wiphis) tracking, follow-up, case management, and reporting. Includes surveillance components. More details in Appendix 9. Pharmacoepidemiology Hub, B.C. Resource for researchers interested in Hood, Jane . Mental Health and Addictions Re- using B.C.’s prescription database, Phar- Tel: 604-707-6393. search Institute (BCMHARI) (no URL) maNet, to study patterns of utilization of pharmacological agents in the treatment of mental illness and addiction. Pharmaceutical Outcomes and Policy Innovations, B.C. Children’s Hospital (POPi) (www.popi.ubc.ca) Described above in Table 9. School of Environmental Health SOEH research includes: Hurrell, Christie. Executive Director, Centre (SOEH) UBC (www.soeh.ubc.ca) • Determinants of exposure for Health and Environment Research • Epidemiology and risk regulation • Knowledge translation T: 604-827-5622. Vaccine Evaluation Centre, BCCH A node of the Canadian Immunization Bettinger, Julie. (www.bcchildrens.ca/Research/Vaccine- Monitoring Program, Active [IMPACT] – a T: 604-875-2422. EvaluationCentre) (www.cps.ca/English/ pediatric hospital-based national active jbettinger@cw.bc.ca. surveillance/impact/impact.htm) surveillance network for adverse events following immunization, vaccine failures and selected infectious diseases in children. Also conducts epidemiological studies. Women’s Health Research Institute Conducts epidemiology studies on Heath, Katherine. Manager, Research (www.whri.org) the health and health care of girls and Development. women. T: 604-875-2424 x 4877. kheath@cw.bc.ca
CLINICAL TRIALS AND PRECLINICAL INFRASTRUCTURE ASSET MAP Biomarker Translation and Development B.C. has a large cohort of researchers who are identifying biomarkers of disease such as cardiovascular events, cancer, CNS and pulmonary diseases, infection, and transplant rejection, and translating these to clinical use. The key institutions involved in biomarker translation and development are listed in Table 11. Information on each of these centres can be found in Appendix 9 (sections 3, 5, 7, and 13). Of the more than 2,100 trials included in this report, 27 (funded with over $1M) involved the translation of biomarkers. TABLE 11. Centres Involved in the Translation and Development of Biomarkers Centre (URL) Biomarker Translation and Development B.C. Cancer Research Centre (www. Diagnostic, prognostic, and predictive tests for cancer using biomarkers. Research bccrc.ca) depts. involved in such development include the Terry Fox Laboratory and Michael Smith Genome Sciences Centre. Centre for Molecular Medicine and Genetic markers that are predictive of severe ADRs for use in diagnostic screening Therapeutics (www.cmmt.ubc.ca) programs; genetic markers of Huntington’s Disease. Centre for Translational and Applied Genomics (CTAG) (www.phsa.ca/AgenciesAndServices/Services/PHSA-Labs/ About-PHSA-Labs/CTAG.htm) Diagnostics and prognostics for cancer, infectious diseases, and inherited syndromes. James Hogg iCAPTURE Centre (Heart Licensed out unique single nucleotide polymorphisms that can predict whether a Lung Institute) (www.iCapture.ubc.ca) patient with sepsis will respond to certain treatments; these are being used in the development of a molecular diagnostic test. Prevention of Organ Failure Centre of Excellence (PROOF) (www.proof.hli.ubc.ca) Blood biomarkers that can identify whether a transplanted organ is being rejected. Pharmaceutical Outcomes and Policy Involved in the identification and translation of biomarkers predictive for drug Innovations, B.C. Children’s Hospital (POPi) (www.popi.ubc.ca) adverse reactions. The Vancouver Prostate Centre PC- Development of microarrays and next generation sequencing technologies for use as TRIADD (www.pctriadd.com) cancer diagnostics and prognostics. Networks Provincial networks have been established to leverage expertise within individual B.C. institutions. These have produced broad-based capabilities that are a lot more than the sum of the parts. The 13 networks listed in Table 12 support clinical studies. TABLE 12. Provincial Networks That Support Clinical Trials Network (URL) Disease-Based Description B.C. Mental Health and Addictions Builds research capacity and generates research that informs policy and practice in Research Network (www.mhanet.ca) the field of mental health. B.C. Pediatric Oncology Network (www. Enhances the community care of children and families by bringing multidisciplinary bccancer.bc.ca/HPI/CancerManagement- teams together to diagnose, manage, and follow-up pediatric patients with malig- Guidelines/Pediatric/default.htm) nancies and blood disorders. 37
Page 1: 1 33 0 34 0 M A G N E T I C V A R 9
Page 4 and 5: ii BRITISH COLUMBIA
Page 6 and 7: 2 EXECUTIVE SUMMARY BRITISH COLUMBI
Page 8 and 9: 4 INTRODUCTION BRITISH COLUMBIA Wit
Page 10 and 11: 6 Health Authority (URL) Key Facili
Page 12 and 13: 8 FIGURE 2. Clinical Trials Units,
Page 14 and 15: 10 Facility (URL if available) Pedi
Page 16 and 17: 12 Facility (URL if available) Mood
Page 18 and 19: 14 Facility (URL if available) Down
Page 20 and 21: 16 Facility (URL if available) Clin
Page 22 and 23: 18 Facility (URL if available) Gast
Page 24 and 25: 20 TABLE 3. Clinical Trials Support
Page 26 and 27: 22 Much clinical research - particu
Page 28 and 29: 24 FIGURE 3. Source of Funds for Cl
Page 30 and 31: 26 BRITISH COLUMBIA FIGURE 7. Thera
Page 32 and 33: 28 BRITISH COLUMBIA Clinical Invest
Page 34 and 35: Disease Area Population Information
Page 36 and 37: 32 CV/Cardiology CNS Pulmonary Canc
Page 38 and 39: 34 TABLE 9. Health Economics and He
Page 42 and 43: 38 TABLE 12. Provincial Networks Th
Page 44 and 45: 40 Network B.C. Investigator’s Ro
Page 46 and 47: 42 Network B.C. Investigator’s Ro
Page 48 and 49: 44 TABLE 14. Independent Clinical T
Page 50 and 51: 46 COMPARATIVE POSITIONING OF B.C.
Page 52 and 53: 48 ACKNOWLEDGEMENTS BRITISH COLUMBI
Page 54 and 55: 50 APPENDIX 1-2 TABLE OF CONTENTS B
Page 56 and 57: 52 PROVINCIAL HEALTH SERVICES AUTHO
Page 58 and 59: 54 BRITISH COLUMBIA Edward Miller C
Page 60 and 61: 56 BRITISH COLUMBIA Radiation Thera
Page 62 and 63: 58 The Unit has 15 Principal Invest
Page 64 and 65: 60 BRITISH COLUMBIA Neonatal Resear
Page 66 and 67: 62 The B.C. Children’s Hospital p
Page 68 and 69: 64 BRITISH COLUMBIA The clinical tr
Page 70 and 71: 66 FRASER HEALTH AUTHORITY BRITISH
Page 72 and 73: 68 BRITISH COLUMBIA tional therapis
Page 74 and 75: 70 PROVIDENCE HEALTH CARE SOCIETY 4
Page 76 and 77: 72 BRITISH COLUMBIA Quality control
Page 78 and 79: 74 Clinical trials investigators in
Page 80 and 81: 76 The facility has 13 investigator
Page 82 and 83: 78 Staffing of the Centre is as fol
Page 84 and 85: 80 Investigators: • Ayas, Najib
Page 86 and 87: 82 BRITISH COLUMBIA Quality control
Page 88 and 89: 84 The Research Group consists of t
Page 90 and 91:
86 BRITISH COLUMBIA Multiple Sclero
Page 92 and 93:
88 BRITISH COLUMBIA Gastroenterolog
Page 94 and 95:
Since the Centre is located in St.
Page 96 and 97:
TABLE A1. Providence Health Care So
Page 98 and 99:
94 BRITISH COLUMBIA FIGURE A9. Cent
Page 100 and 101:
96 BRITISH COLUMBIA The Unit suppor
Page 102 and 103:
TABLE A2. CFRI Program-affiliated R
Page 104 and 105:
100 BRITISH COLUMBIA Quality contro
Page 106 and 107:
102 BRITISH COLUMBIA • Knowledge
Page 108 and 109:
104 Its staffing is as follows: Stu
Page 110 and 111:
106 APPENDIX 3. QUALITY CONTROL/ QU
Page 112 and 113:
APPENDIX 5. CLINICAL TRIALS TRAININ
Page 114 and 115:
APPENDIX 5. Clinical Trials Trainin
Page 116 and 117:
112 APPENDIX 6 TABLE OF CONTENTS BR
Page 118 and 119:
6.1 Clinical Trials Researchers Lis
Page 120 and 121:
Page 122 and 123:
Page 124 and 125:
Page 126 and 127:
Page 128 and 129:
Page 130 and 131:
Page 132 and 133:
Page 134 and 135:
Page 136 and 137:
Page 138 and 139:
Page 140 and 141:
Page 142 and 143:
Page 144 and 145:
Page 146 and 147:
Page 148 and 149:
Page 150 and 151:
Page 152 and 153:
Page 154 and 155:
Page 156 and 157:
Page 158 and 159:
Page 160 and 161:
Page 162 and 163:
Page 164 and 165:
Page 166 and 167:
Page 168 and 169:
Page 170 and 171:
Page 172 and 173:
Page 174 and 175:
Page 176 and 177:
Page 178 and 179:
Page 180 and 181:
Page 182 and 183:
Page 184 and 185:
Page 186 and 187:
Page 188 and 189:
Page 190 and 191:
Page 192 and 193:
Page 194 and 195:
Page 196 and 197:
Page 198 and 199:
Page 200 and 201:
Page 202 and 203:
Page 204 and 205:
Page 206 and 207:
Page 208 and 209:
Page 210 and 211:
Page 212 and 213:
Page 214 and 215:
Page 216 and 217:
Page 218 and 219:
Page 220 and 221:
Page 222 and 223:
Page 224 and 225:
Page 226 and 227:
Page 228 and 229:
Page 230 and 231:
Page 232 and 233:
Page 234 and 235:
Page 236 and 237:
Page 238 and 239:
Page 240 and 241:
Page 242 and 243:
Pediatrics INSTITUTION EMAIL URL DI
Page 244 and 245:
Pediatrics (cont’d) INSTITUTION E
Page 246 and 247:
Page 248 and 249:
Page 250 and 251:
Page 252 and 253:
248 APPENDICES 7-13 TABLE OF CONTEN
Page 254 and 255:
250 TABLE A3. Patient and Addiction
Page 256 and 257:
252 TABLE A3. Patient and Addiction
Page 258 and 259:
APPENDIX 8. PROVINCIAL AND NATIONAL
Page 260 and 261:
APPENDIX 8. Provincial And National
Page 262 and 263:
258 APPENDIX 9. Healthcare Research
Page 264 and 265:
APPENDIX 9. Healthcare Research Cen
Page 266 and 267:
Page 268 and 269:
Page 270 and 271:
Page 272 and 273:
Page 274 and 275:
Page 276 and 277:
Page 278 and 279:
Page 280 and 281:
Page 282 and 283:
Page 284 and 285:
Page 286 and 287:
Page 288 and 289:
APPENDIX 10. NATIONAL AND INTERNATI
Page 290 and 291:
Networks In Which B.C.’s Clinical
Page 292 and 293:
Page 294 and 295:
Page 296 and 297:
APPENDIX 11. INDEPENDENT CLINICAL T
Page 298 and 299:
APPENDIX 11. Independent Clinical T
Page 300 and 301:
Page 302 and 303:
Page 304 and 305:
Page 306 and 307:
Page 308 and 309:
Page 310 and 311:
APPENDIX 12. PRECLINICAL STUDIES SE
Page 312 and 313:
APPENDIX 12. Preclinical Studies Se
Page 314 and 315:
APPENDIX 12. Preclinical Studies Se
Page 316 and 317:
312 B.C. Centre for Disease Control
Page 318 and 319:
314 University of Victoria Brenda D
Page 320:
316 BRITISH COLUMBIA
show all

Clinical Trials and Preclinical Infrastructure Asset Map - Genome BC

Create successful ePaper yourself

Delete template?

Save as template?